HALO Halozyme Therapeutics Inc

Price (delayed)

$45.04

Market cap

$6.21B

P/E Ratio

14.62

Dividend/share

N/A

EPS

$3.08

Enterprise value

$6.97B

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in ...

Highlights
HALO's net income has surged by 167% year-on-year and by 8% since the previous quarter
HALO's EPS has surged by 157% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of HALO
Market
Shares outstanding
137.95M
Market cap
$6.21B
Enterprise value
$6.97B
Valuations
Price to earnings (P/E)
14.62
Price to book (P/B)
23.83
Price to sales (P/S)
13.15
EV/EBIT
23.08
EV/EBITDA
22.85
EV/Sales
14.79
Earnings
Revenue
$471.57M
EBIT
$302.16M
EBITDA
$305.2M
Free cash flow
$287.26M
Per share
EPS
$3.08
Free cash flow per share
$2.09
Book value per share
$1.89
Revenue per share
$3.43
TBVPS
$8.44
Balance sheet
Total assets
$1.16B
Total liabilities
$901.99M
Debt
$877.65M
Equity
$260.26M
Working capital
$877M
Liquidity
Debt to equity
3.37
Current ratio
8.85
Quick ratio
8.06
Net debt/EBITDA
2.49
Margins
EBITDA margin
64.7%
Gross margin
83.2%
Net margin
92.2%
Operating margin
63.8%
Efficiency
Return on assets
38.9%
Return on equity
202.6%
Return on invested capital
19%
Return on capital employed
28.8%
Return on sales
64.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
-0.2%
1 week
-7.19%
1 month
-13.02%
1 year
11.21%
YTD
12.01%
QTD
2.36%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$471.57M
Gross profit
$392.45M
Operating income
$300.84M
Net income
$434.92M
Gross margin
83.2%
Net margin
92.2%
HALO's net income has surged by 167% year-on-year and by 8% since the previous quarter
The net margin has soared by 87% YoY
The company's operating income has surged by 52% YoY and by 9% QoQ
HALO's gross profit is up by 42% YoY and by 8% QoQ

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
P/E
14.62
P/B
23.83
P/S
13.15
EV/EBIT
23.08
EV/EBITDA
22.85
EV/Sales
14.79
HALO's EPS has surged by 157% year-on-year and by 8% since the previous quarter
The stock's price to earnings (P/E) is 15% less than its last 4 quarters average of 17.1
The company's equity rose by 32% QoQ
HALO's price to book (P/B) is 23% lower than its last 4 quarters average of 31.1 and 10% lower than its 5-year quarterly average of 26.5
The company's revenue rose by 42% YoY and by 6% QoQ
The price to sales (P/S) is 3.3% lower than the 5-year quarterly average of 13.6

Efficiency

How efficient is Halozyme Therapeutics business performance
Halozyme Therapeutics's return on assets has surged by 55% YoY and by 3.5% QoQ
The ROE has grown by 31% YoY but it has contracted by 16% from the previous quarter
HALO's return on sales is up by 18% year-on-year and by 11% since the previous quarter
HALO's return on invested capital is down by 15% year-on-year but it is up by 7% since the previous quarter

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 29% higher than its total liabilities
The company's total assets rose by 20% YoY and by 5% QoQ
Halozyme Therapeutics's quick ratio has increased by 13% from the previous quarter
Halozyme Therapeutics's debt to equity has plunged by 74% YoY and by 24% from the previous quarter
The company's equity rose by 32% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.